百时美-话题@MedSci - 梅斯（MedSci）

#百时美#

60篇内容 | 2159人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1764477, encodeId=ac241e64477b9, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=肥厚型心肌病患者新选择！联拓生物合作伙伴百时美施贵宝公司的Camzyos (mavacamten) 获美国FDA批准, objectType=article, longId=725731, objectId=7110e25731dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7110e25731dc, replyNumber=0, likeNumber=94, createdTime=2022-08-14, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7110e25731dc, moduleTitle=肥厚型心肌病患者新选择！联拓生物合作伙伴百时美施贵宝公司的Camzyos (mavacamten) 获美国FDA批准, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7110e25731dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764475, encodeId=1a751e64475fb, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=卫材与百时美施贵宝在ADC药物达成或高达30亿美元战略合作协议, objectType=article, longId=212888, objectId=cecd21288851, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cecd21288851, replyNumber=0, likeNumber=98, createdTime=2021-09-07, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cecd21288851, moduleTitle=卫材与百时美施贵宝在ADC药物达成或高达30亿美元战略合作协议, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=cecd21288851)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764472, encodeId=ba231e6447272, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=百时美施贵宝与Agenus签署15.6亿美元协议，获得AGEN1777全球**授权, objectType=article, longId=211532, objectId=14ab21153250, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14ab21153250, replyNumber=0, likeNumber=81, createdTime=2021-11-13, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14ab21153250, moduleTitle=百时美施贵宝与Agenus签署15.6亿美元协议，获得AGEN1777全球**授权, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=14ab21153250)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764473, encodeId=7bca1e6447303, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=百时美施贵宝公布了III期临床研究CheckMate -227第1部分随访结果, objectType=article, longId=210709, objectId=659b210e098a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=659b210e098a, replyNumber=0, likeNumber=92, createdTime=2021-06-25, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=659b210e098a, moduleTitle=百时美施贵宝公布了III期临床研究CheckMate -227第1部分随访结果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=659b210e098a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764476, encodeId=bca81e64476f8, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌, objectType=article, longId=221346, objectId=ab662213469b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab662213469b, replyNumber=0, likeNumber=97, createdTime=2022-08-22, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab662213469b, moduleTitle=FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ab662213469b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764471, encodeId=8e031e64471c2, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=百时美施贵宝血液病创新药Luspatercept上市申请获CDE优先审评, objectType=article, longId=206759, objectId=7050206e59ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7050206e59ba, replyNumber=0, likeNumber=65, createdTime=2021-10-16, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7050206e59ba, moduleTitle=百时美施贵宝血液病创新药Luspatercept上市申请获CDE优先审评, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7050206e59ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764474, encodeId=24ee1e6447491, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=百时美施贵宝公布III期临床研究CheckMate -9LA两年随访数据，结果喜人！, objectType=article, longId=210359, objectId=837e210359f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=837e210359f2, replyNumber=0, likeNumber=89, createdTime=2021-09-11, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=837e210359f2, moduleTitle=百时美施贵宝公布III期临床研究CheckMate -9LA两年随访数据，结果喜人！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=837e210359f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764468, encodeId=58c81e644685d, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=百时美施贵宝宣布CheckMate870临床研究达到主要研究终点，未发现新的安全性信号, objectType=article, longId=194191, objectId=15161941913d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15161941913d, replyNumber=0, likeNumber=85, createdTime=2020-12-04, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15161941913d, moduleTitle=百时美施贵宝宣布CheckMate870临床研究达到主要研究终点，未发现新的安全性信号, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=15161941913d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764463, encodeId=f8611e6446396, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=百时美施贵宝控告吉利德的CAR-T细胞疗法Yescarta专利侵权案胜诉，将赢得7.52亿美元的赔偿, objectType=article, longId=184904, objectId=574418490463, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=574418490463, replyNumber=0, likeNumber=79, createdTime=2020-07-21, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=574418490463, moduleTitle=百时美施贵宝控告吉利德的CAR-T细胞疗法Yescarta专利侵权案胜诉，将赢得7.52亿美元的赔偿, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=574418490463)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764470, encodeId=3c171e64470ad, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=百时美施贵宝斥131亿美元收购心血管药物研发商 , objectType=article, longId=201808, objectId=854e201808dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=854e201808dc, replyNumber=0, likeNumber=80, createdTime=2021-07-18, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=854e201808dc, moduleTitle=百时美施贵宝斥131亿美元收购心血管药物研发商 , moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=854e201808dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764467, encodeId=9dc11e64467fb, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=百时美施贵宝宣布，美国与欧洲监管机构已接受欧狄沃（纳武利尤单抗）联合伊匹木单抗及有限疗程化疗用于肺癌一线治疗的申请, objectType=article, longId=191924, objectId=e2a4191924a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e2a4191924a2, replyNumber=0, likeNumber=91, createdTime=2020-08-15, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e2a4191924a2, moduleTitle=百时美施贵宝宣布，美国与欧洲监管机构已接受欧狄沃（纳武利尤单抗）联合伊匹木单抗及有限疗程化疗用于肺癌一线治疗的申请, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e2a4191924a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764466, encodeId=52fb1e64466a2, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=百时美施贵宝的1-磷酸鞘氨醇受体调节剂ozanimod，获FDA批准治疗复发型多发性硬化症, objectType=article, longId=190924, objectId=13da19092498, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13da19092498, replyNumber=0, likeNumber=87, createdTime=2020-05-17, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13da19092498, moduleTitle=百时美施贵宝的1-磷酸鞘氨醇受体调节剂ozanimod，获FDA批准治疗复发型多发性硬化症, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=13da19092498)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764469, encodeId=4f1d1e64469ea, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌, objectType=article, longId=194250, objectId=8f001942503c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f001942503c, replyNumber=0, likeNumber=56, createdTime=2021-01-30, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f001942503c, moduleTitle=FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8f001942503c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764459, encodeId=11ff1e644591a, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=双免疫联合治疗肺癌添新证，百时美施贵宝宣布CheckMate-227 1a达到总生存期的共同主要终点, objectType=article, longId=176189, objectId=bfbc1e6189e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfbc1e6189e0, replyNumber=0, likeNumber=82, createdTime=2020-02-24, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfbc1e6189e0, moduleTitle=双免疫联合治疗肺癌添新证，百时美施贵宝宣布CheckMate-227 1a达到总生存期的共同主要终点, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=bfbc1e6189e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764465, encodeId=c4fc1e64465fe, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=百时美施贵宝的PD-1单抗Opdivo组合针对晚期胰腺癌的临床试验失败, objectType=article, longId=188481, objectId=680d18848160, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=680d18848160, replyNumber=0, likeNumber=75, createdTime=2020-09-18, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=680d18848160, moduleTitle=百时美施贵宝的PD-1单抗Opdivo组合针对晚期胰腺癌的临床试验失败, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=680d18848160)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764460, encodeId=cdd71e6446056, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=百时美施贵宝公布欧狄沃®（nivolumab，纳武利尤单抗注射液）用于晚期经治非小细胞肺癌患者汇总五年总生存（OS）数据, objectType=article, longId=179251, objectId=fc171e9251bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc171e9251bb, replyNumber=0, likeNumber=92, createdTime=2019-11-18, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc171e9251bb, moduleTitle=百时美施贵宝公布欧狄沃®（nivolumab，纳武利尤单抗注射液）用于晚期经治非小细胞肺癌患者汇总五年总生存（OS）数据, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fc171e9251bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764464, encodeId=e6181e6446438, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=百时美施贵宝宣布向FDA申请其CAR-T细胞疗法liso-cel的许可, objectType=article, longId=184956, objectId=2ccf1849567a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ccf1849567a, replyNumber=0, likeNumber=79, createdTime=2020-07-12, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ccf1849567a, moduleTitle=百时美施贵宝宣布向FDA申请其CAR-T细胞疗法liso-cel的许可, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2ccf1849567a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764461, encodeId=fa7c1e644611d, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=百时美施贵宝公布CheckMate 227最终临床结果，数据喜人！, objectType=article, longId=180267, objectId=e3f218026ef1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3f218026ef1, replyNumber=0, likeNumber=88, createdTime=2019-12-12, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3f218026ef1, moduleTitle=百时美施贵宝公布CheckMate 227最终临床结果，数据喜人！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e3f218026ef1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764457, encodeId=bb051e644570a, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=百时美施贵宝公布欧狄沃（纳武利尤单抗注射液）治疗经治非小细胞肺癌患者的长期生存汇总分析结果, objectType=article, longId=163563, objectId=b02416356319, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b02416356319, replyNumber=0, likeNumber=75, createdTime=2019-10-28, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b02416356319, moduleTitle=百时美施贵宝公布欧狄沃（纳武利尤单抗注射液）治疗经治非小细胞肺癌患者的长期生存汇总分析结果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b02416356319)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1764462, encodeId=d7211e644629b, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, objectTitle=百时美施贵宝和蓝鸟生物报告其CAR-T细胞疗法候选药物idecabtagene vicleucel的阳性结果, objectType=article, longId=184397, objectId=4dad18439e2a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4dad18439e2a, replyNumber=0, likeNumber=72, createdTime=2020-02-28, rootId=0, userName=ms1467340776200723, userId=c9b037737594, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4dad18439e2a, moduleTitle=百时美施贵宝和蓝鸟生物报告其CAR-T细胞疗法候选药物idecabtagene vicleucel的阳性结果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4dad18439e2a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

百时美

2020-05-29

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

肥厚型心肌病患者新选择！联拓生物合作伙伴百时美施贵宝公司的Camzyos (mavacamten) 获美国FDA批准

2022-08-14

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

卫材与百时美施贵宝在ADC药物达成或高达30亿美元战略合作协议

2021-09-07

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

百时美施贵宝与Agenus签署15.6亿美元协议，获得AGEN1777全球**授权

2021-11-13

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

百时美施贵宝公布了III期临床研究CheckMate -227第1部分随访结果

2021-06-25

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌

2022-08-22

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

百时美施贵宝血液病创新药Luspatercept上市申请获CDE优先审评

2021-10-16

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

百时美施贵宝公布III期临床研究CheckMate -9LA两年随访数据，结果喜人！

2021-09-11

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

百时美施贵宝宣布CheckMate870临床研究达到主要研究终点，未发现新的安全性信号

2020-12-04

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

百时美施贵宝控告吉利德的CAR-T细胞疗法Yescarta专利侵权案胜诉，将赢得7.52亿美元的赔偿

2020-07-21

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

百时美施贵宝斥131亿美元收购心血管药物研发商

2021-07-18

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

百时美施贵宝宣布，美国与欧洲监管机构已接受欧狄沃（纳武利尤单抗）联合伊匹木单抗及有限疗程化疗用于肺癌一线治疗的申请

2020-08-15

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

百时美施贵宝的1-磷酸鞘氨醇受体调节剂ozanimod，获FDA批准治疗复发型多发性硬化症

2020-05-17

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌

2021-01-30

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

双免疫联合治疗肺癌添新证，百时美施贵宝宣布CheckMate-227 1a达到总生存期的共同主要终点

2020-02-24

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

百时美施贵宝的PD-1单抗Opdivo组合针对晚期胰腺癌的临床试验失败

2020-09-18

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

百时美施贵宝公布欧狄沃®（nivolumab，纳武利尤单抗注射液）用于晚期经治非小细胞肺癌患者汇总五年总生存（OS）数据

2019-11-18

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

百时美施贵宝宣布向FDA申请其CAR-T细胞疗法liso-cel的许可

2020-07-12

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

百时美施贵宝公布CheckMate 227最终临床结果，数据喜人！

2019-12-12

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

百时美施贵宝公布欧狄沃（纳武利尤单抗注射液）治疗经治非小细胞肺癌患者的长期生存汇总分析结果

2019-10-28

ms1467340776200723 (审核中...)

前往app查看评论内容

#百时美#

百时美施贵宝和蓝鸟生物报告其CAR-T细胞疗法候选药物idecabtagene vicleucel的阳性结果

2020-02-28

科室
- - 订阅+
  - 更多科室
工具
服务